<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The novel antiarrhythmic drug K201 (4-[3-{1-(4-<z:chebi fb="0" ids="22744">benzyl</z:chebi>)piperidinyl}<z:chebi fb="0" ids="26294">propionyl</z:chebi>]-7-<z:chebi fb="8" ids="32772">methoxy</z:chebi>-2,3,4,5-tetrahydro-1,4-<z:chebi fb="0" ids="48684">benzothiazepine</z:chebi> monohydrochloride) is currently in development for treatment of <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>K201 not only controls intracellular calcium release by the <z:chebi fb="0" ids="8925">ryanodine</z:chebi> receptors, but also possesses a ventricular action that might predispose to <z:hpo ids='HP_0001664'>torsade de pointes</z:hpo> <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The anti- and proarrhythmic effects of K201 were investigated in the anesthetized canine <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001678'>atrioventricular block</z:hpo> model </plain></SENT>
<SENT sid="3" pm="."><plain>Two doses of K201 (0.1 and 0.3mg/kg/2 min followed by 0.01 and 0.03 mg/kg/30 min i.v.) were tested in 4 serial experiments in dogs with normally conducted sinus rhythm (n=10) and in <z:hpo ids='HP_0001664'>torsade de pointes</z:hpo>-susceptible dogs with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001678'>atrioventricular block</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Susceptibility was assessed with <z:chebi fb="0" ids="4681">dofetilide</z:chebi> (0.025 mg/kg/5 min i.v.) </plain></SENT>
<SENT sid="5" pm="."><plain>Beat-to-beat variability of repolarization was quantified as short-term variability of left ventricular monophasic action potential duration </plain></SENT>
<SENT sid="6" pm="."><plain>In dogs with normally conducted sinus rhythm, both doses of K201 prolonged ventricular repolarization whereas only the higher dose prolonged atrial repolarization </plain></SENT>
<SENT sid="7" pm="."><plain>At <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001678'>atrioventricular block</z:hpo>, <z:chebi fb="0" ids="4681">dofetilide</z:chebi> induced <z:hpo ids='HP_0001664'>torsade de pointes</z:hpo> in 9 of 10 dogs </plain></SENT>
<SENT sid="8" pm="."><plain>K201 did neither suppress nor prevent <z:chebi fb="0" ids="4681">dofetilide</z:chebi>-induced <z:hpo ids='HP_0001664'>torsade de pointes</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>K201 dose-dependently prolonged ventricular repolarization </plain></SENT>
<SENT sid="10" pm="."><plain>In contrary to the lower dose, the higher dose did increase beat-to-beat variability of repolarization (from 1.2 ± 0.3 to 2.9 ± 0.8 ms, P&lt;0.05) and resulted in spontaneous, repetitive <z:hpo ids='HP_0001664'>torsade de pointes</z:hpo> <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> in 1 of 7 dogs; Programmed electrical stimulation resulted in <z:hpo ids='HP_0001664'>torsade de pointes</z:hpo> in 2 more dogs </plain></SENT>
<SENT sid="11" pm="."><plain>In conclusion, both doses of K201 showed a class III effect </plain></SENT>
<SENT sid="12" pm="."><plain>No relevant antiarrhythmic effects against <z:chebi fb="0" ids="4681">dofetilide</z:chebi>-induced <z:hpo ids='HP_0001664'>torsade de pointes</z:hpo> were seen </plain></SENT>
<SENT sid="13" pm="."><plain>Only at the higher dose a proarrhythmic signal was observed </plain></SENT>
</text></document>